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Abstract
Massively Parallel Sequencing (MPS) allows sequencing of entire exomes and genomes to now be done at reasonable cost,
and its utility for identifying genes responsible for rare Mendelian disorders has been demonstrated. However, for a complex
disease, study designs need to accommodate substantial degrees of locus, allelic, and phenotypic heterogeneity, as well as
complex relationships between genotype and phenotype. Such considerations include careful selection of samples for
sequencing and a well-developed strategy for identifying the few ‘‘true’’ disease susceptibility genes from among the many
irrelevant genes that will be found to harbor rare variants. To examine these issues we have performed simulation-based
analyses in order to compare several strategies for MPS sequencing in complex disease. Factors examined include genetic
architecture, sample size, number and relationship of individuals selected for sequencing, and a variety of filters based on
variant type, multiple observations of genes and concordance of genetic variants within pedigrees. A two-stage design was
assumed where genes from the MPS analysis of high-risk families are evaluated in a secondary screening phase of a larger
set of probands with more modest family histories. Designs were evaluated using a cost function that assumes the cost of
sequencing the whole exome is 400 times that of sequencing a single candidate gene. Results indicate that while requiring
variants to be identified in multiple pedigrees and/or in multiple individuals in the same pedigree are effective strategies for
reducing false positives, there is a danger of over-filtering so that most true susceptibility genes are missed. In most cases,
sequencing more than two individuals per pedigree results in reduced power without any benefit in terms of reduced
overall cost. Further, our results suggest that although no single strategy is optimal, simulations can provide important
guidelines for study design.
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Introduction
Over the past two decades, advances in genome technology
have greatly facilitated the discovery of genetic variation which
confer increased susceptibility to disease, first through genetic
maps of microsatellite markers which allowed mapping and then
positional cloning of relatively high-penetrance disease predis-
posing mutations in genes such as BRCA1 [MIM 113705] and
BRCA2 [MIM 600185], and then through the ability of high
throughput, relatively low cost platforms containing 300,000–
1,000,000 single nucleotide polymorphisms (SNPs) which have
greatly facilitated the identification of common genetic variants
conferring only modest increases in disease risk. To date, over
800 disease susceptibility loci in ,150 human diseases/traits
have been identified at genome-wide significance [1], thus
validating this approach. In addition, less frequent, moderate-
risk susceptibility alleles have been identified through resequen-
cing of candidate genes selected on the basis of biological
plausibility. However, it has also become clear that for many
diseases and human traits, the known loci explain only relatively
small fractions of the total genetic variance. While further
genome-wide association studies using ever-higher density arrays,
larger sample sizes and encompassing copy number variations
will account for some of the missing genetic effect, it is unlikely
that this proportion will increase markedly via this approach.
The latest improvement in technology can be directed towards
resolving this and identifying the missing heritability that seems a
general phenomenon in many human diseases. There are several
ways in which such technology can identify disease associated
genetic variation; through resequencing of genomic regions
implicated through GWAS in the hope/expectation of identify-
ing rarer variants associated with higher risk that are tagged by
the SNPs arrayed in the GWAS platforms [2], and through the
possible identification of rare high-penetrance mutations in
several disease susceptibility genes. Although it is impossible to
predict which of the above hypotheses are correct and it is
possible that the missing heritability will be explained by a
combination of them all, it is clear that this may now be tested
through the latest genomic technology. Massively Parallel
Sequencing (MPS) provides order of magnitude improvement
in throughput over Sanger sequencing enabling ‘‘genome-wide’’
sequencing applications in single sample preparations.
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exome massively parallel sequencing in the identification of a gene
for a rare Mendelian disorder (Miller Syndrome) based on analysis
of only four unrelated individuals [3]. Here the authors benefited
from the fact that not only did the four individuals have mutations
in the same gene, but that all four had the same mutation. This
considerably facilitated the task of proving that these mutations
were in fact causal for the disorder. In another case it was the
observation of multiple (causal) variants in the same gene that was
the key observation leading to the identification of the suscepti-
bility gene [4]. Subsequently whole-exome sequencing has been
used to identify genes for other rare Mendelian diseases whose
genetic basis was previously unknown (reviewed in Ng et al. [5]),
typically using only a small number of individuals. However, to
date, the success in rare Mendelian diseases has not been
replicated in common diseases, even those with a demonstrated
large genetic component.
How then can we best use these new sequencing capabilities to
find rare high-penetrance disease-associated variants for common/
complex diseases? The challenges in moving from the Mendelian
situation to multi-factorial diseases or other human traits are
many. First and foremost among these is genetic heterogeneity, in
which mutations in many such relatively rare, but high-risk, genes
give rise to nearly identical phenotypes. For example, in breast
cancer, although BRCA1 and BRCA2 account for many of the
striking multiple-case breast cancer families, recently it has become
apparent through candidate gene resequencing studies that very
rare mutations in at least five additional genes contribute to the
unexplained familial aggregation [6]. Nevertheless, it is clear that
the genetic basis of the majority of high-risk breast cancer
pedigrees remains unresolved. A more extreme example is
delineated by McClellan and King [7] for hereditary deafness in
which no fewer than 48 genes have been demonstrated to have
mutations predisposing to this condition. In addition to multiple
loci, it appears to be a general feature of most populations that
there are a large number of different highly penetrant mutations in
any given disease susceptibility gene; In BRCA2 for example, at
least 2000 distinct pathogenic mutations have been reported, along
with ,800 other sequence variants whose pathogenicity is still
uncertain (Breast Cancer Information Core database [8]).
Another complication for studies of common complex diseases is
that even when a gene is segregating in a family and is responsible
for the majority of the cases, there are likely to be one or more
affected individuals that do not share the predisposing mutation
since the disease is common by definition. Although often these
may be distinguished from ‘genetic cases’’ by such factors as age at
onset, severity, disease subtypes, etc. these phenocopies still cause
complications for the study of complex traits by MPS. There is also
the possibility that some apparent high-risk families are the result
of aggregation of many common moderate-risk loci segregating
within the family, mimicking an autosomal dominant pattern of
inheritance, and/or an unusual cluster of environmentally caused
(non-familial/genetic) cases of the disease.
While a number of others have investigated strategies for the
statistical analysis of rare variants from candidate gene or whole
exome/genome resequencing studies [9–13], there has not been a
similar consideration of family-based designs in which the
detection of comparatively higher penetrance alleles are the
objective.
In general the success of sequence-based approaches (whether
whole exome or whole genome or other targeted strategy) for
identifying susceptibility genes will depend on the genetic
architecture of the underlying disease. Some have argued that
most of the so-called ‘missing heritability’ is due to as yet
undiscovered relatively common variation with very small effects,
while others have argued that evolutionary forces are more likely
to generate large numbers of very rare mutations in key sets of
genes, each conferring relatively high risks of disease [7], In a
recent editorial, Cirulli and Goldstein [14] argue that until whole
genome sequencing costs are sufficiently low to allow case-control
approaches to be sufficiently powered, ‘‘the primary engines of
discovery’’ are likely to be sequencing of individuals in families
having multiple affected individuals; and selecting individuals from
extremes of a trait distribution. Further, they outline the utility of
using shared variants in families followed by further co-segregation
studies of candidate variants, as well as bioinformatics analyses to
narrow down the list of potential disease-associated variants. They
concluded that ‘‘The development of appropriate test statistics that
combine these different lines of evidence is a current priority for
the field’’.
In this paper, we illustrate these concepts using a simulated two-
stage whole-exome MPS experiment of a hypothetical common
disease and derive some general guidelines and considerations for
the design of such studies.
Methods
Assumptions
The assumed genome. We first assume that there are
25,000 genes in the genome, each of which may have rare genetic
variation unrelated to the disease. In our simulations, we take an
entirely agnostic view and assume that each of these genes may
harbor disease predisposing variants as well as unrelated variants.
That is, we will not select genes of interest for a second stage based
on pathways or function (although from a practical point, we
might in fact prioritize for the analysis based on these factors).
Based on the empirical data derived from published whole-exome
sequencing studies [15], we assume that there are 400 rare
missense variants (rms) and 20 truncating/splice junction (TSJ)
non-disease related variants identified per sequenced exome.
For the ‘true’’ disease risk variants, we assume that these will be
detected with a sensitivity of 90% i.e., that 90% of the sequence
variants that are present in the genomic/exomic DNA will be
detected by the particular Exome Capture/MPS platform used.
We recognize that different types of variants (e.g., frameshifts vs.
single nucleotide substitutions) may in fact differ slightly in their
probability of detection; however, this is dependent on many
factors and is not likely to affect our overall results. Although some
current exon-capture systems do not cover the whole-exome,
newer and developing products are approaching full exome-
coverage, and with the addition of reverse strand sequencing of the
targeted capture of the exons missed by the available kits from
Agilent and Nimblegen, complete coverage of the exome will soon
be achieved. However, we have assumed a somewhat lower value
for sensitivity to account for other types of genetic variation that
may not be detectable by exome sequencing approach (e.g., deep
intronic variants causing a splicing abnormality; or cis-acting
regulatory elements). For simplicity we further assume that true
pathogenic mutations in each of the relevant disease genes are
comprised of 50% rare missense (rms) changes, and 50%
substitutions occurring either at consensus splice sites (both
intronic and exonic) or are nonsense mutations or small
insertions/deletions leading to premature truncation (TSJ). This
reflects the uncertainty of knowing in advance the mutational
spectrum of an unknown set of genes; for a subset of simulated
conditions, we have examined the effect of higher or lower
proportions of TSJ mutations. We further assume that each
variant detected has been assessed for sequence quality and has
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(,0.005). Lastly we assume that for the rare missense variants, we
can employ a filter based on bioinformatics sequence analysis of
conservation across species, severity of amino acid substitution,
predicted effects on splicing, etc. that will exclude two-thirds of
unrelated variants but only 10% of true pathogenic missense
variants. For example, we might require that missense variants
affect residues that are conserved in mammals and also be non-
conservative, which for the BRCA1 and BRCA2 genes results in
approximately these figures. This filter will reduce the number of
extraneous variants at the expense of missing some true variants.
Underlying Genetic Architecture
Because the underlying genetic architecture is likely to have a
big effect on the optimal strategies to identify disease loci, we
considered the following situations. First, we assumed that
combined, the total set of rare high risk variants in the genome
acting on the disease accounted for in aggregate a total of a
familial relative risk of 1.33. For many of the common cancers this
represents about 1/3 of the overall familial risk and approximately
half of the unexplained risk. For diseases with stronger familial
components such as many of the autoimmune disorders, this will
be a lower proportion of the total genetic variance, but could be
about the same proportion of the unexplained heritability since in
many of those diseases variation at the MHC accounts for a
substantial fraction. In our main simulations we assumed that the
frequency of the disease in individuals without a high-risk allele
was 0.02 and that the increased risk conferred by such mutations
was 56, 7.56,1 0 6,1 5 6,o r2 0 6this baseline risk. In all cases we
assumed the combined frequency of such alleles in any given gene
was 0.0001. The descriptions of the models are shown in Table 1.
Based on this model, and assuming that the loci act multiplica-
tively on risk, it is straightforward to calculate the number of such
loci to achieve the desired overall familial risk of 1.33 as
N=log(1.33)/log(lRk) where lRk is the locus-specific familial risk to
first-degree relatives as calculated from the allele frequencies, and
genotype relative risks (see e.g., Skol et al. [16]) as shown in
Table 1.
Basic strategies to be compared
Our basic design for all the simulations to be examined in this
report is a two-stage design, where in the first stage, a relatively
small number of very high-risk pedigrees (presumed to be likely to
carry high-penetrance mutations in susceptibility gene) are
analyzed by whole exome (or whole genome) MPS, followed by
more conventional testing of candidate genes identified in stage I
in a larger set of families that may have less dramatic family
histories, by such techniques as High Resolution Melt analysis
(HRM) or Denaturing High Performance Liquid Chromatogra-
phy (DHPLC) which provide high-throughput mutation scanning
at relatively low cost. Within this framework we compare designs
in which one, two, or three individuals are sequenced per family.
In all cases, we select those individuals who are most likely to be
mutation carriers based on their phenotype and pedigree position.
Figure 1a shows the pedigree structure assumed for the stage I
analyses. Sequencing a single individual per family has lower up-
front sequencing costs and typically it is easier to find appropriate
families (we need only 1 sample with 3 ug of genomic DNA) in this
approach; however, potentially more genes need to be screened in
stage II. When multiple individuals are sequenced, there could be
a loss of power if one of the two sequenced individuals is a
phenocopy and only concordant variants are selected for further
study; in addition, there are the increased costs of sequencing two
or more individuals per family.
Filters applied to variants/genes
In order to reduce the number of genes not associated with
disease to be analyzed in the second stage, it will be necessary to
apply one or more additional filtering steps in addition to the
simple bioinformatics and frequency filters described previously.
We can distinguish three classes of filter: concordance of the
genetic variants and the disease in pedigrees; the requirement of
observation of variants in the same gene in multiple families; and
filters based on the type of variants observed. In addition, these
three filtering strategies can be combined; we could for example
only pass genes on to stage II that are observed to be concordant
in two families, one of which is a truncating variant.
Concordance Filter
For those situations in which we sample two or more individuals
from each pedigree, the first filter will be to pass only variants and
their respective genes for further validation if the variant is shared
between all sequenced individuals. The efficiency of this filter
depends on the degree of relationship between the individuals
sequenced. In general, for two individuals related by degree D, we
would exclude a proportion of (2
D+122)/(2
D+121) irrelevant
variants. For cousins, for example, we would exclude 14/15 (93%)
of such variants. When more than two individuals are sequenced,
the situation is more complicated, but using the same approach
similar probabilities can be calculated. In the case of the pedigree
in Figure 1a, 45/46 (98%) of all non-disease related variants would
be eliminated. Of course, it is also important that this process does
not eliminate true susceptibility genes. The fraction of excluded
true variants will depend on the genetic model, pedigree structure,
and pedigree phenotypes. For example, under model II, the two
cousins would be expected to be share a true disease susceptibility
allele segregating in the family 73% of the time and all three
sequenced individuals would be expected to share such an allele
67% of the time.
Multiple Pedigree Filter
Beyond this ‘‘concordance filter’’ which, in any case, does not
apply to the single individual sequence per pedigree approach,
another strategy for distinguishing between the true susceptibility
genes and genes containing spurious variants is the observation of
variants in the same gene in multiple families. This filter can be
tuned by requiring fewer or more observations in independent
pedigrees. In our simulations, we have considered the situation
where 1, 2, or 3 variants are required in a given gene for that gene
to be passed to stage II. It should be noted that these filters apply
only to variants that have passed the initial filters of sequence
quality, frequency, and the bioinformatics screen as applied to rare
Table 1. Genetic Models Examined.
Model GRR Penetrance FRR
No. of loci for
FRRtotal=1.33
I 20 0.4 1.036 8
II 15 0.3 1.02 15
III 10 0.2 1.008 35
IV 7.5 0.15 1.0036 68
V 5 0.10 1.0016 179
Susceptibility allele frequency=0.0001, sporadic rate=0.02. GRR: genotype
relative risk; FRR: familial relative risk.
doi:10.1371/journal.pone.0023221.t001
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of non-relevant variants are passed to the next step.
Variant type filter
Although the bioinformatics filter reduces the number of
missense/intronic variants that need to be considered, there were
still be a large number of these variants that pass these initial
filters. Given that truncating or consensus splice variants have a
higher likelihood, a priori, of being pathogenic, it seems sensible
that these could be given preference in choosing genes to
sequence. The difficulty is that for some disease genes, the
majority of pathogenic mutations are missense changes, which
would result in potentially missing these genes.
Table 2 summarizes the filters that will be examined in this
paper.
Stage II Criteria
Each gene that passes through the series of filters outlined above
will be sequenced in a set of families that are less highly selected
than in stage I, but depending on the disease, would still have a
reasonable probability of having a genetic basis. Figure 1b shows
the pedigree used for the stage II simulations. We assume that we
will use a low-cost, relatively high-throughput method such as
High Resolution Melt analysis (HRM) or Denaturing High
Performance Liquid Chromatography (DHPLC), or even poten-
tially a second round of targeted capture MPS that sequences all
the stage II genes at the same time and evaluates pools of samples
from the stage II families. We take as our criteria for stage II
confirmation of a given gene, that a qualifying rare missense or
truncating/splice variant is found in e.g, 3 or more of the stage II
families. Under this scenario, we can calculate the probability that
the index case in each pedigree carries a mutation in a disease
gene using e.g., the LINKAGE package [17,18], and then using a
simple binomial probability, calculate the probability that these
would appear in 3 or more of 250 independent trials. The
probabilities of the index case carrying a disease allele in one such
gene are 0.061, 0.040, 0.019, 0.011, and 0.005 for models I–V
respectively with corresponding probabilities of being validated
Figure 1. Pedigrees used in stage I and stage II. Panel A: pedigree structure for stage I. Individuals sequenced are indicated by an arrow: ID 8 is
sequenced when one individual is sequenced; IDs 8 and 11 when two are sequenced; IDs 8, 5 and 11 when three are sequenced. Panel B: pedigree
structure for stage II. ID 8 is analyzed.
doi:10.1371/journal.pone.0023221.g001
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respectively. To calculate the probability that a gene that is
unrelated to the disease of interest will meet the criteria of 3+
families having a qualifying variant in that gene we assume that
there is a 0.1% chance that such a variant will be found in that
gene given that we will apply the same frequency and bioinfor-
matics filters in this stage as before. Note that this is still a 5-fold
increase over the population allele frequency assumed for the
disease-causing variants. For example, under this assumption the
associated probability that a non-disease-related gene would have
3 or more qualifying variants in 250 pedigrees is 0.002. So even if
300 false genes are screened in stage II, the expected number of
false positives is less than 1 and the probability of more than 2 false
positives being validated in stage II is 0.023. Table 3 shows the
probabilities of being validated for both true susceptibility genes
and non-disease related genes for a range of sample sizes and
thresholds for the number of observed variants.
Evaluation of Strategies and Filters
In choosing a strategy/filter combination, our goal is to
maximize the number of ‘‘true’’ genes identified, at a minimum
of cost/labor expended. A big part of this cost will be the
unnecessary screening of false genes in a large number of
individuals in stage II. The cost function we used to evaluate the
strategies is as follows: We assume a cost of $4000 for each
sequenced exome and a cost of $10 for mutation screening an
average sized gene in each individual sample in stage II. For these
calculations we assumed the middle sample size from table 3 of
250 pedigrees in stage II. The overall cost of the study is then:
Cost of stage I :$ 4000   Np   Ns
Cost of stage II :$ 10   250  
number of genes passed to stage II ðÞ
where Np is the number of pedigrees in stage I, and Ns is the
number of individuals sequenced per pedigree in stage I. The total
cost is then the sum of the stage I and stage II costs. The essential
feature that we want to capture here is the trade-off between the
high cost of screening a single individual for the entire exome (or
genome) compared to the cost of screening individually many
promising candidate genes arising from the whole exome
approach.
Simulation Procedure
In order to assess the performance of the various strategies and
filters under the assumed genetic models, we performed a
simulation study as described below. The first step was to calculate
the probabilities that each person in the pedigree carried a true
risk allele under the given susceptibility model. We did this by
using the program SLINK [19,20] with 10,000 simulated
pedigrees, using parameters corresponding to each genetic model,
an assumed allele frequency of 0.0001 and complete linkage
disequilibrium and no recombination between the disease allele
and the presumed mutation (i.e., the disease allele is the variant
being simulated). Using these probabilities we then select (though
generation of a series of uniform-[0,1) random numbers) which of
the N true genes (if any) were segregating in each family. Next, in a
similar fashion the probability that the other individual sequenced
in the pedigree is also carrying the mutation is used to determine if
Table 2. Selected filters examined in the simulation.
Filter One Case per pedigree Two Cases per Pedigree
N1RV All genes with a RV All genes with a concordant RV
N1TS All genes with a TSJ All genes with a concordant TSJ
N2RV All genes with RVs in 2+ pedigrees All genes with RVs in 2+ pedigrees, at least one pedigrees
concordant
N2TS All genes with RVs in 2+ pedigrees, at least 1 RV is TSJ All genes with RVs in 2+ pedigrees, at least 1 RV is TSJ, at
least one pedigree concordant
N3RV All genes with RVs in 3+ pedigrees All genes with RVs in 3+ pedigrees, at least one pedigree
concordant
RV: rare variant; TSJ: truncating/splice junction variant.
doi:10.1371/journal.pone.0023221.t002
Table 3. Effect of different sample sizes and validation
thresholds on type I and type II error in stage II.
Number of variants needed for
validation
Model nPeds $2 $3 $4
Not Associated 150 0.010 0.0004 0.00002
250 0.026 0.002 0.0001
350 0.049 0.005 0.0005
I 150 1.0 0.99 0.98
250 1.0 1.0 1.0
350 1.0 1.0 1.0
II 150 0.98 0.94 0.85
250 1.0 1.0 0.99
350 1.0 1.0 1.0
III 150 0.78 0.54 0.32
250 0.95 0.86 0.70
350 0.99 0.96 0.90
IV 150 0.49 0.23 0.09
250 0.76 0.52 0.30
350 0.90 0.74 0.54
V 150 0.17 0.04 0.01
250 0.36 0.13 0.04
350 0.52 0.26 0.10
nPeds: number of pedigrees in stage II. Entries are the probability of meeting
the specified validation criteria for a given sample size and model. Models are
described in Table 1.
doi:10.1371/journal.pone.0023221.t003
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variant. Then we assign 400 rare missense and 20 truncating/
splice non-disease related variants randomly selected from 25,000
genes to each sequenced individual, keeping track of which of the
25,000 genes each variant is in, and where required, if it is
concordant in the pedigree. This is repeated for each pedigree in
the data set. Lastly we apply the designated additional filters to
determine under each scenario which genes are passed to stage II.
The previous steps were independently repeated 100 times and the
number of true and false genes passed to stage II recorded for each
replicate. These are then used to calculate the total cost of the
study.
Results
In the presentation of the results in the manuscript, we will focus
on the key aspects of the analysis and findings and only present
results for a selected set of filters and sample sizes (the detailed
results for all models, filters, and sample sizes can be found in
Table S1). Although in the tables to follow, we present only
averages across the 100 replicates, the standard deviations as
calculated from the 100 replicates were generally between 1 and 2
for the number of true genes identified and (as one would expect
from this type of counting process) roughly the square root of the
average number of false genes. For example for 30 pedigrees, and
the filter requiring two variants in the same gene, under model II
we identify on average 8.5 genes of the 15 true genes and 210 false
genes with respective standard deviations of 1.3 and 13.5.
It is instructive to look at the number of ‘‘false’’ genes that are
selected for screening in stage II, as this will in most cases have the
greatest impact on the overall cost of the study. Table 4 provides
these figures as a function of sample size for the five filters shown
in table 2 under the scenarios of sequencing one, two, or three
individuals per pedigree, and requiring at least one variant to be
concordant when multiple individuals were sequenced. Because
these false positives are independent of the disease model, they
only have random variation across the various models and thus the
figures provided are averages across the five models examined.
The first line of table 4 points out the clear need to employ some
sort of filtering strategy to reduce the number of potential genes
that would need to be analyzed in stage II; even if we sequence two
individuals and use concordance as a filter, for large numbers of
pedigrees, the number of genes is quite large. In all cases, it is
important to remember that these figures only include variants
that have already passed through frequency filters (e.g., are not
found in the 1000 Genomes Project database [21]) and
bioinformatics filter that we assumed would eliminate 70% of
non-disease related variants while passing 90% of true disease
genes on to validation in stage II.
Table 5 examines the effects of sample size, number of
individuals sequenced per pedigree, and filter on the number of
true genes found and total study cost for Model II, in which there
are 15 unknown disease genes in the genome, each conferring a
15-fold increased risk of disease.
Table 6 examines the study cost and the proportion of genes
identified in stage I for a fixed sample size of 60 exomes sequenced
(with differing numbers of sequenced individuals) for the five filters
and five models of disease. These results demonstrate that the
requirement that two or more pedigrees have variants in a given
gene can effectively reduce the cost, with or without the
concordance filter, and that the power lost due to this requirement
depends on the expected number of true genes and the sample
size. The higher the ratio of sample size to the expected number of
genes, the smaller the decrease in power. From the table we can
also see that requiring at least one variant be TSJ is another
effective filter, under the assumption that half of the true disease
variants are of this type. Note also that for models with many
disease loci but where each has a smaller effect on disease risk,
fewer genes are identified using any of the designs with cost
,$1M, especially when considering the number of genes that are
contributing. For example in the model IV where there are 68
susceptibility genes each conferring a relative risk of disease of 7.5-
fold, the best designs only identify slightly over 10% of these 68
loci.
Only considering truncating variants may be a good strategy
depending on the proportion of pathogenic variants that are of this
type. In examining the results presented thus far, it is important to
remember that we assumed that 50% of all disease alleles were
assume to be those that result in a truncated (or null) protein or
could be assumed to severely influence normal splicing of the gene.
Because this may certainly vary between different disease genetic
architectures, we have examined the effect of varying this
proportion for select models. Here we will only consider two
filters, and focus on the intermediate model with 15 genes each
with rare alleles conferring a risk of 156over population rates. In
these cases we examine the effect of varying the proportion of
pathogenic mutations in each gene that are of the TSJ variety from
the 0.5 that we have assumed thus far, and look at values of 0.3
and 0.7 to determine the effect of this proportion on the efficiency
of the various strategies. Table 7 shows the effect of these different
assumptions on the number of true disease genes identified in stage
I.
Discussion
In this set of simulations we have attempted to show some of the
more important aspects and principles of design of studies
involving MPS of common human disease. Our overall approach
is modeled on the two-stage GWAS design in which cases and
controls are assayed on a dense (500KR1M) SNP chips, followed
Table 4. Number of false genes passed to stage II for various
filtering strategies, averaged across the five disease models.
Filter Ns
Np=
10
Np=
20
Np=
30
Np=
40
Np=
60
N1RV 1 1359 2641 3857 5006 7119
2 174 346 520 687 1022
3 87 175 262 347 518
N1TS 1 199 396 591 785 1169
2 2 55 07 51 0 0 1 4 9
3 1 22 43 85 07 4
N2RV 1 34 138 305 527 1111
2 15 60 133 225 460
3 1 24 59 61 5 9 3 1 6
N2TS 1 9 37 83 144 309
2 4 17 37 65 138
3 3 13 28 48 102
N3RV 1 0 5 16 36 117
2 151 8 4 1 1 2 3
3 162 0 4 3 1 2 4
Np: number of pedigrees in stage I; Ns: number of individuals sequenced per
pedigree in stage I; Filters are described in Table 2.
doi:10.1371/journal.pone.0023221.t004
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the top N (e.g., 10,000) SNPs (ranked by p-value) are tested on a
(usually) larger independent set of cases and controls. For MPS
studies our overall design is a first stage in which whole-exome
sequencing is performed on samples from individuals in excep-
tionally high-risk families (or other extreme phenotype). In our
case, the second stage is not a set of SNPs or variants, but a screen
by sequencing of a relatively small number of genes that meet the
criteria applied in the first stage, and in a larger number of
individuals using a relatively inexpensive high-throughput screen-
ing strategy using methods such as HRM, DHPLC, or even
targeted capture MPS. Within this framework we have attempted
to look at the trade-off between the power to detect true disease
loci against the vast number of false positives that will be generated
in any MPS experiment. More importantly, we have examined the
efficacy/efficiency of a variety of filtering strategies in reducing the
number of false positives without dramatically affecting the power
to detect the true disease susceptibility loci. Liu and Leal have also
explored the strategies for two-stage designs in the context of
whole-exome sequencing of a series of cases and controls with
individual interesting variants or genes evaluated in a second stage
[22]. In their case, the two primary strategies compared were to
evaluate individual variants in the second stage or to evaluate
through re-sequencing the genes in which those variants were
identified. They concluded that sequence-based replication is
generally advantageous if the stage I sample size is relatively small,
as many variants will not be identified in the initial sequencing.
The methods proposed by ourselves [13] and Price et al [10] both
incorporate filters based on allele frequency and in silico analysis of
sequence variants in order to create a more powerful aggregate test
of the hypothesis that rare variants in a gene are contributing to
disease risk than methods based on simply counting the numbers
of variants observed in cases and controls as in e.g., [11]. The
problem we address here differs from the case-control design
examined in the above studies in at least two aspects. First, our
assumption is that the individual disease alleles are much rarer
than those proposed above and would not be amenable (even in
aggregate) to a case-control approach; and second, we are
considering the whole exome rather than a specific gene or
pathway as is typically done in the case-control situation as
analyzed above. It is not clear how these methods would work
when applied to 20,000 genes; it is likely that the required sample
size to detect the (even large) effects of many such alleles with
correction for the multiple comparisons inherent in such a
genome-wide approach would be prohibitive. Kryukov et al.
[23] have specifically examined the power of whole-exome
sequencing studies using extreme phenotypes and concluded that
for reasonable affect sizes, detecting the effects of rare alleles in
individual genes would be possible, although the sample sizes
would be in the 1000s for whole-exome sequencing and the
number of individuals that would need to be phenotyped to
provide adequate selection of extremes would be substantially
larger. Thus we focused our paper on the problem of vanishingly
rare variants of large effect and the use of family studies to identify
the specific genes harboring such variants.
Given that there are a large number of possible genetic
architectures underlying each disease, and in most of these cases
we can only make educated guesses about the true genetic basis.
However, in the analyses presented here we have explicitly or
implicitly assumed several key features. First, we assume that a
substantial proportion of the ‘‘missing’’ genetic variance is due to
individually rare alleles that confer moderate to high increased risk
of disease (5–20 fold). Second, we have assumed that the pedigrees
available for whole exome sequence analysis will be likely to be
segregating a pathogenic mutation in one such gene, although not
all cases in the pedigree are necessarily due to this mutation (i.e.,
phenocopies). Additionally we have assumed that each sequenced
exome will contain a large number of rare missense variants that
are independent of disease and a smaller number of protein
truncating variants, even after filtering by frequency and by in silico
analyses. We have assumed that this filter would reduce the
number of rare missense variants by 70%; although this may seem
somewhat arbitrary we note that our experience in analyzing a
number of genes, shows that this level of filtering is easily
achievable even using available multiple species protein sequence
alignments. Further such a filter can be easily adjusted to provide
more (or less) stringent filtering by requiring different degrees of
evolutionary sequence conservation and/or more radical changes
of the affected residue.
Taken as a whole, the results presented in Tables 4, 5, 6, and 7
demonstrate that while the choice of an appropriate strategy will
depend on a variety of factors, the optimal degree of filtering will
depend on the sample size as well as the choice of the number of
individuals sequenced in each pedigree; there is no single optimal
strategy. As Table 4 shows, when stringent filtering based on
multiple variants in the same gene in different pedigrees is applied
(e.g., N3RV) the number of false positives is approximately the
same for a fixed number of pedigrees no matter how many
individuals are sequenced, indicating that the concordance aspect
is not as important since a given variant has to only be concordant
in a single pedigree and so there is a balance between the number
of exomes sequenced and the additional filtering, whereas for the
looser filter N1RV there are large differences in the number of
false genes as a function of the number of sequenced per pedigree.
Table 4 also demonstrates that requiring multiple rare variants
that are potentially pathogenic (based on a simple bioinformatics
Table 7. Number of true genes identified as a function of proportion of pathogenic mutations that are type TSJ.
Np(Ns)=20(1) Np(Ns)=20(2) Np(Ns)=40(1)
nTrue Cost nTrue Cost nTrue Cost
Filter=N2RV pTSJ=0.5 5.2 4.4 5.2 3.2 10.6 15.0
Filter=N1TS pTSJ=0.3 4.9
a 3.3
a 7.9
a
Filter=N1TS pTSJ=0.5 7.1 10.9 5.2 3.0 10.7 21.5
Filter=N1TS pTSJ=0.7 8.7
a 6.7
a 12.5
a
pTSJ: proportion of pathogenic mutations that are type TSJ; Np: number of pedigrees in stage I; Ns: number of individuals sequenced per pedigree in stage I. nTrue:
number of true susceptibility genes passed to the validation in stage II; cost is in 100k USD.
aCost does not vary with pTSJ, therefore the number should be equal to that for Filter=N1TS pTSJ=0.5. Filters are described in Table 2.
doi:10.1371/journal.pone.0023221.t007
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sequencing is a very effective strategy in reducing the number of
false positives (and hence the cost). Of course, this will also reduce
the number of true genes identified, with the magnitude depending
on the true underlying genetic architecture.
Under the models examined, one point that is evident from our
results is that as the number of pedigrees increases, the cost of
doing the study increases more rapidly than the increase in the
number of susceptibility genes identified, particularly when only a
single individual is sequenced per pedigree. This is true under a
variety of different filtering strategies.
Often the choice of strategy will be determined by the
availability of a sufficient number of suitable pedigrees and,
beyond that by the ability to get sufficient quantity and quality of
DNA from the appropriate members of the pedigree in the two or
three individuals per pedigree case. In many cases it is easier to get
larger number of pedigrees suitable for analysis in stage II. In this
regard, it is useful that there are designs that are more or less
equivalent in terms of cost and number of true genes identified
using each strategy. In choosing which cases within a pedigree to
sequence in stage I, there is typically a trade-off between power
and false positive rate. If they are too closely related (e.g. siblings),
the concordance filter cannot effectively exclude false positive
genes; on the other hand, if they are too distantly related,
particularly without intervening affected relatives and a common
disease, the probability that the two individuals are not sharing a
true high-risk mutation is increased, and the concordance filter will
have a higher likelihood of rejecting a true disease gene.
We have made both explicit and implicit assumptions in our
simulations, including the numbers of genes in the genome, the
distribution of variants across those genes, the proportion of
pathogenic variants of a given type, and the sensitivity of MPS
sequencing in detecting true pathogenic variants. Although
inaccuracies in these assumptions may affect some of the finer
details of our results, we believe that the overall conclusions of our
study are sound. Clearly the biggest factor influencing our ability
to identify novel susceptibility alleles for complex human disease is
the underlying genetic architecture which unfortunately is
essentially unknowable, although often epidemiological and other
data such as linkage studies, can provide some rough guides. If
much of the genetic variance is due to many rare alleles of
relatively modest effect in many different genes, and if the disease
is common, it is likely that different approaches will have to be
developed to identify these genes.
Our study shows that the choice of the appropriate design and
filtering strategies will likely depend on many factors, and there is
no ‘‘one-size fits all’’ recommendation. The choice of design
depends on funds available, the ability of identifying high-risk
families such as that typified in our simulations, as well as the
ability to obtain DNA samples from the best individuals within
each pedigree. Sequencing three cases per family does not add
much additional variant filtering compared with the two
individuals per pedigree case, and thus does not meaningfully
reduce the overall cost. However, this strategy does result in lower
power as a result of the exclusion of true genes due to the higher
probability of one of the three cases being a phenocopy.
Nevertheless, we note that there may be situations where it would
be desirable to sequence three cases if, for example, only siblings
were available. Nevertheless, our results provide some general
guidelines that indicate that a reasonable fraction of moderate to
high penetrance genes can be identified for complex diseases with
practical and economical study designs. As costs of MPS
sequencing drop for both whole exome and whole genome
approaches, different strategies may become economically feasible.
In particular, it may be possible to perform the second stage on
larger numbers of genes using targeted sequence capture, or all
available families could be screened in the first stage. In either
case, there will still be a need for effective filtering strategies,
particularly in the case of whole genome sequencing. Although the
strategy employed and the sequencing method employed are
clearly important, the key to success in identifying novel
susceptibility for common disease will ultimately rely on the
availability of large series of well-characterized families with many
cases of the disease of interest and with the appropriate collections
of biospecimens available for study. We recommend that before
embarking on whole-exome or whole-genome studies in complex
human diseases, careful consideration be given to the concepts
discussed in this paper under a set of disease-specific plausible
genetic models. We encourage interested readers to use the data in
the supplemental data to repeat these analyses using relative costs
of exome sequencing to candidate gene screening and sample sizes
that are pertinent to their situation. To assist in this effort, the
simulation program used in this study is available from the authors
on request.
Supporting Information
Table S1 Simulation results for all disease models, filters and
sample sizes.
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